GenSight Biologics launches a capital increase of about 20ME

Paris, June 22, 2017 – GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, eligible PEA-PME), (” GenSight Biologics ” or ” the Company “), a biopharmaceutical company dedicated to the discovery and development of gene therapy solutions for the treatment of neurodegenerative diseases of the retina and the central nervous system, today announced the launch of a capital increase of approximately€ 20M is reserved to a category of persons.

Download the free guide
Boost your gains

The funds raised will be allocated to the preparation for the launch of GS010 in Europe and the United States, and in particular to the financing related to the marketing, market access and the establishment of a commercial infrastructure.

GS010, is currently in Phase III, and positive results at 96 weeks of a Phase I/II have recently been published for the treatment of hereditary optic neuropathy Leber (NOHL). The second candidate GS030, which has obtained orphan drug designation in the United States in the treatment of pigmentary retinopathy, is currently in the toxicity study regulatory and is expected to enter into clinical study Phase I/II in the 4th quarter of 2017 [1].

The gross proceeds of the transaction is expected to amount to approximately € 20 million. This operation is intended to fund the preparation of the commercialisation of GS010, and would increase the financial visibility of the Company until the 1st quarter of 2019.

This funding would result in the issuance of a maximum number of about 3 908 090 new shares with a nominal value of 0.025 euros per share and representing approximately 20% of the share capital of the Company on a non-diluted basis. The subscription price per share will be determined in accordance with the 22nd resolution of the combined general Meeting of may 31, 2017.

The fundraiser will be open exclusively to the categories of natural or legal persons defined in the 22nd resolution mentioned above (i.e., investing as usual in the pharmaceutical industry, biotechnology, ophthalmology, neurodegenerative diseases or medical technology.) The subscription price per share will be set with a maximum discount of 15% compared to the last three stock market sessions preceding the fixing of the price, namely, from June 20 to June 22, 2017, pursuant to the 22nd resolution of the combined general Meeting of may 31, 2017.

The issuance of the new shares will be the subject of a procedure of construction of book orders from qualified investors in accordance with section 3.2(a) of the directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003 (as amended) and included in the category of persons satisfying determined characteristics by the 22nd resolution, on the territory of the EEA, and in some other countries.

The Company will announce the result of the fundraising as soon as possible after the closing of the order book in a press release later. The settlement-delivery of new shares and admission is expected on 27 June 2017 on the regulated market of Euronext Paris.

In conjunction with the determination of the definitive terms and conditions of the capital increase, the Company will sign a commitment to conservation for a period of 90 days after the date of pricing of the capital increase, subject to the usual exceptions. Persons acting on behalf of the Company (that is to say, the members of the executive committee, directors and officers) will also sign commitments to the conservation of a similar duration in respect of the shares of the Company they hold.

Guggenheim Securities, LLC and Oddo BHF SCA act as Levels of Book Associated.

A listing prospectus comprising the reference document 2016, filed with the AMF on April 28, 2017 under the number R. 17-036, available free of charge on the internet sites of the Company ( and/or of the Autorité des marchés financiers (, and a Transaction Note, containing a summary of the prospectus in French and in English will be submitted to the AMF in order to obtain a visa. Public attention is drawn to the risk factors relating to the Company and its activity, presented in chapter 4 of its document de référence.

This press release does not constitute a prospectus under the Prospectus directive or an offer to the public

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply